These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 24113377

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. LPA1/3 signaling mediates tumor lymphangiogenesis through promoting CRT expression in prostate cancer.
    Lin YC, Chen CC, Chen WM, Lu KY, Shen TL, Jou YC, Shen CH, Ohbayashi N, Kanaho Y, Huang YL, Lee H.
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Oct; 1863(10):1305-1315. PubMed ID: 30053596
    [Abstract] [Full Text] [Related]

  • 4. High Glucose Induces VEGF-C Expression via the LPA1/3-Akt-ROS-LEDGF Signaling Axis in Human Prostate Cancer PC-3 Cells.
    Huang YL, Lin YC, Lin CC, Chen WM, Chen BPC, Lee H.
    Cell Physiol Biochem; 2018 Oct; 50(2):597-611. PubMed ID: 30317243
    [Abstract] [Full Text] [Related]

  • 5. Pitavastatin inhibits lysophosphatidic acid-induced proliferation and monocyte chemoattractant protein-1 expression in aortic smooth muscle cells by suppressing Rac-1-mediated reactive oxygen species generation.
    Kaneyuki U, Ueda S, Yamagishi S, Kato S, Fujimura T, Shibata R, Hayashida A, Yoshimura J, Kojiro M, Oshima K, Okuda S.
    Vascul Pharmacol; 2007 Apr; 46(4):286-92. PubMed ID: 17178255
    [Abstract] [Full Text] [Related]

  • 6. Lysophosphatidic acid increases the proliferation and migration of adipose‑derived stem cells via the generation of reactive oxygen species.
    Kang S, Han J, Song SY, Kim WS, Shin S, Kim JH, Ahn H, Jeong JH, Hwang SJ, Sung JH.
    Mol Med Rep; 2015 Oct; 12(4):5203-10. PubMed ID: 26134517
    [Abstract] [Full Text] [Related]

  • 7. Aromatic hydrocarbon receptor inhibits lysophosphatidic acid-induced vascular endothelial growth factor-A expression in PC-3 prostate cancer cells.
    Wu PY, Lin YC, Lan SY, Huang YL, Lee H.
    Biochem Biophys Res Commun; 2013 Aug 02; 437(3):440-5. PubMed ID: 23831623
    [Abstract] [Full Text] [Related]

  • 8. Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia.
    Zeng Y, Kakehi Y, Nouh MA, Tsunemori H, Sugimoto M, Wu XX.
    Prostate; 2009 Feb 15; 69(3):283-92. PubMed ID: 19025891
    [Abstract] [Full Text] [Related]

  • 9. Lysophosphatidic acid induces prostate cancer PC3 cell migration via activation of LPA(1), p42 and p38alpha.
    Hao F, Tan M, Xu X, Han J, Miller DD, Tigyi G, Cui MZ.
    Biochim Biophys Acta; 2007 Jul 15; 1771(7):883-92. PubMed ID: 17531530
    [Abstract] [Full Text] [Related]

  • 10. Signal transduction responses to lysophosphatidic acid and sphingosine 1-phosphate in human prostate cancer cells.
    Gibbs TC, Rubio MV, Zhang Z, Xie Y, Kipp KR, Meier KE.
    Prostate; 2009 Oct 01; 69(14):1493-506. PubMed ID: 19536794
    [Abstract] [Full Text] [Related]

  • 11. Effects of lysophosphatidic acid on calpain-mediated proteolysis of focal adhesion kinase in human prostate cancer cells.
    Park JJ, Rubio MV, Zhang Z, Um T, Xie Y, Knoepp SM, Snider AJ, Gibbs TC, Meier KE.
    Prostate; 2012 Nov 01; 72(15):1595-610. PubMed ID: 22473839
    [Abstract] [Full Text] [Related]

  • 12. Lysophosphatidic acid-regulated mitogenic ERK signaling in androgen-insensitive prostate cancer PC-3 cells.
    Kue PF, Taub JS, Harrington LB, Polakiewicz RD, Ullrich A, Daaka Y.
    Int J Cancer; 2002 Dec 20; 102(6):572-9. PubMed ID: 12447997
    [Abstract] [Full Text] [Related]

  • 13. Beta-catenin, cancer, and G proteins: not just for frizzleds anymore.
    Malbon CC.
    Sci STKE; 2005 Jul 12; 2005(292):pe35. PubMed ID: 16014605
    [Abstract] [Full Text] [Related]

  • 14. Lysophosphatidic acid stimulates p21-activated kinase in vascular smooth muscle cells.
    Schmitz U, Thömmes K, Beier I, Vetter H.
    Biochem Biophys Res Commun; 2002 Mar 01; 291(3):687-91. PubMed ID: 11855845
    [Abstract] [Full Text] [Related]

  • 15. Lysophosphatidic acid (LPA) enhances the metastatic potential of human colon carcinoma DLD1 cells through LPA1.
    Shida D, Kitayama J, Yamaguchi H, Okaji Y, Tsuno NH, Watanabe T, Takuwa Y, Nagawa H.
    Cancer Res; 2003 Apr 01; 63(7):1706-11. PubMed ID: 12670925
    [Abstract] [Full Text] [Related]

  • 16. Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells.
    Qi C, Park JH, Gibbs TC, Shirley DW, Bradshaw CD, Ella KM, Meier KE.
    J Cell Physiol; 1998 Feb 01; 174(2):261-72. PubMed ID: 9428812
    [Abstract] [Full Text] [Related]

  • 17. Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells.
    Hasegawa Y, Murph M, Yu S, Tigyi G, Mills GB.
    Mol Oncol; 2008 Jun 01; 2(1):54-69. PubMed ID: 19081821
    [Abstract] [Full Text] [Related]

  • 18. RAFTK/Pyk2 mediates LPA-induced PC12 cell migration.
    Park SY, Schinkmann KA, Avraham S.
    Cell Signal; 2006 Jul 01; 18(7):1063-71. PubMed ID: 16199135
    [Abstract] [Full Text] [Related]

  • 19. Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3.
    Lin CI, Chen CN, Lin PW, Chang KJ, Hsieh FJ, Lee H.
    Biochem Biophys Res Commun; 2007 Nov 30; 363(4):1001-8. PubMed ID: 17923111
    [Abstract] [Full Text] [Related]

  • 20. Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase.
    Ruisanchez É, Dancs P, Kerék M, Németh T, Faragó B, Balogh A, Patil R, Jennings BL, Liliom K, Malik KU, Smrcka AV, Tigyi G, Benyó Z.
    FASEB J; 2014 Feb 30; 28(2):880-90. PubMed ID: 24249637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.